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In radionuclide therapy, the patient is injected with relatively high amounts of therapeutic 
radiopharmaceutical which localises to target tissue and emits ionising radiation. 
Unfortunately, a perfectly targeting radiopharmaceutical has not been discovered and part 
of the radiopharmaceutical accumulates to healthy tissues, which are also thus irradiated. 
In order to ensure safe use, the absorbed dose of radiation-sensitive organs must be 
monitored. 
 
Internal radiation dosimetry in the field of medical physics is measurement, calculation 
and assessment of the absorbed dose from pharmaceuticals labelled with radionuclides. 
Typically, assessment is based on blood samples, external radiation probe measurements 
or imaging. The last ten years has been a time of rapid development in the field of nuclear 
medicine imaging. Hybrid imaging using single photon computed emission tomography 
(SPECT) combined with computed tomography (CT) enables the estimation of organ 
function and the following of the kinetics of radiopharmaceuticals, with high localisation 
precision. In addition to technical improvements, developments in image reconstruction 
algorithms have made quantitative SPECT/CT imaging possible. Combining recent 
advancements, the patient specific dosimetry of radionuclide therapies has become 
possible and is an interesting field of study in nuclear medicine. 
 
The focus of this thesis is on patient specific dosimetry of 177Lu labelled somatostatin 
analogue 177Lu-DOTA-Tyr3-octreotate (177Lu-DOTATATE) treatments and 
development of internal dosimetry software. 177Lu-DOTATATE is a radiopharmaceutical 
that binds to somatostatin receptors and is used to treat patients with metastatic 
neuroendocrine tumours. Recent studies have shown significant treatment outcome 
improvements with 177Lu-DOTATATE when compared to previously used somatostatin 
analogue treatments. However, the kidneys are the healthy organ which receives the 
highest amount of radiation dose from 177Lu-DOTATATE treatments and could be the 
organ that limits the number of treatments a patient can tolerate. In addition, absorbed 
dose to kidneys varies highly from patient to patient and thus patient specific dosimetry 
is recommended. Despite many years of dosimetry research and the existence of several 
published scientific dosimetry tools, there is no clinically validated kidney dosimetry 
software for 177Lu-DOTATATE treatments.  The aim of this thesis was to study 
quantification accuracy of 177Lu radionuclide using SPECT/CT imaging and to study 
 
ii 
mean absorbed doses to kidneys and dose distribution characteristics of 177Lu-
DOTATATE. A streamlined voxel level absorbed dose software for clinical practice was 
developed and validated for kidney dosimetry of 177Lu-DOTATATE treatments. 
 
The effect of reconstruction methods on 177Lu quantification accuracy was studied using 
an anthropomorphic phantom. The phantom was filled with known 177Lu sources and 
scanned with patient imaging protocol using one SPECT/CT camera at Helsinki 
University Central Hospital (HUCH). Acquired data were reconstructed using different 
image compensation methods and results were compared with known source activities in 
the phantom. It was found that Monte Carlo simulation based scatter compensation and 
SPECT detector response compensation improved 177Lu quantification accuracy 
considerably. Similar findings were also observed with data from patients treated with 
177Lu-DOTATATE. 
 
A Monte Carlo simulation study using simplified kidney models and a realistic XCAT 
digital phantom was carried out to investigate absorbed dose distribution of 177Lu. A fast 
absorbed dose calculation method (sMC) was also tested and later implemented into the 
developed dosimetry software. Two main findings were that electrons emitted by 177Lu 
can be assumed to absorb locally when the resolution of the imaging system is taken into 
account and the photon cross-irradiation can contribute significantly to total absorbed 
dose especially in the vicinity of highly active volumes. 
 
Using 177Lu-DOTATATE patient data, two different kidney absorbed dose calculation 
methods were compared. Comparing the mean kidney absorbed dose with the estimated 
maximum absorbed dose, it was observed that 177Lu-DOTATATE accumulates unevenly 
to kidney causing significantly heterogeneous dose distribution within kidneys. In 
addition, a simplified imaging protocol was found to be adequate for dosimetry purposes 
and was later adopted clinical practice. 
 
Combining previous findings new voxel level dosimetry software was developed. The 
clinical feasibility of the proposed software was tested with digital phantom simulations 
and reanalysing patient data from 177Lu-DOTATATE treatments. The software was found 
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Neuroendocrine tumours (NETs) are relative rare (about 230 incidences per year in 
Finland [1]) neoplasms that can arise from different endocrine and nervous system cells. 
Interestingly, the incidence of NE Ts has been reported to be markedly increased in 
Canada [2], United States [3] and Europe [4], which partly reflects the increased 
availability of advanced radiological imaging and diagnostic methods. 
Gastroenteropancreatic NETs (GEP-NET) typically grow slowly and are observed as 
incidental findings during surgery, after extensive growth or when hormonal excretion of 
tumour causes clinical symptoms [3]. Patients with symptoms suggestive of NETs should 
be referred to a centre that is specialised in these diseases and histological and 
immunohistochemistry tests are mandatory to confirm the diagnosis [4]. Based on 
immunohistochemistry markers to reflect tumours proliferation activity (Ki67 and mitotic 
count), NET are classified into  neuroendocrine tumour (G1 or G2) or into neuroendocrine 
carcinoma (G3) grades [5]. Symptoms and outcomes vary enormously among NET 
patients. Relative 5-year survival for pancreatic NETs varies from over 90% to less than 
10%, depending on grade, stage and the site of origin of the tumour [6, 7]. 
 
Currently the only curative treatment for GEP-NETs is surgery. Unfortunately, over 80% 
of patients have metastases in spleen, liver or in both and thus pharmacological treatment 
and peptide receptor radionuclide therapy (PRRT) are the only options to suppress tumour 
growth and spread [3]. The standard treatment for NETs of any size is somatostatin 
analogues. Tumour response to the somatostatin treatment is generally considered to be 
poor, but disease stabilisation of 50%-60% has been reported [4]. 
 
Most of the GEP-NETs overexpress somatostatin receptor subtype 2 that can be targeted 
with radiolabelled pharmaceuticals. Promising clinical trial data has been published about 
PRRT using 177Lu-[DOTA0,Tyr3]-octreotate (177Lu-DOTATATE, Lutathera®, AAA) 
radiopharmaceutical [8-12]. This year a randomized clinical phase III trial investigating 
-off date [13]. The study included 229 
patients from 41 different sites with inoperable and somatostatin receptors expressing 
GEP-NETs. Patients were randomised into 177Lu-DOTATATE treatment group (111 
patients) and to a control group (110 patients). At the time of interim analysis, the median 
progression free time had not been reached in the 177Lu-DOTATATE treatment group 
while it was 8.4 months in the control group treated with conventional high-dose 
octreotide long-acting repeatable (LAR) somatostatin analogue. For the 177Lu-
DOTATATE group, progression free time was estimated to be 40 months.  
 
In PRRT, a radiolabelled peptide is typically introduced to a patient by an intravenous 
infusion. The radiopharmaceutical is distributed within the patient by perfusion and partly 
accumulated to tumour cells. The free radiopharmaceutical is secreted or metabolised by 
kidneys and liver, respectively. This pharmacokinetic process is characterised by the 
pharmaceutical properties and organ functions of the patient, but the biological effect of 
treatment is mostly based on radiation emitted by the radionuclide. The major drawback 






and thus dosing should be personalised to avoid possible healthy tissue complications. 
Conventional dosing methods rely on an amount of injected activity scaled by weight or 
body surface area, but these methods fail to take into account the pharmacokinetics or 
radiation characteristics of the radionuclide. Fortunately, radionuclides used in PRRT are 
typically selected so that they emit, in addition to locally ionising radiation ( - or  
particles), also x-rays or  radiation, which can be localised and quantified with a gamma 
camera. Ideally, the radiation exposure from the radiopharmaceutical, measured as 
absorbed dose, can then be estimated from the images. Image based dosimetry is not a 
novel concept and has been investigated as long as there have been imaging methods 
available. However, within the last ten years developments in reconstruction algorithms 
and the increasing availability of computing power have made quantitative imaging and 
image based dosimetry possible in daily practice. It should be noted that current image 
based dosimetry methods are based mostly on post-therapeutic imaging and there is no 
method available that could predict the outcome of the radionuclide therapy. 
 
In this study, dosimetry methods for radionuclide therapy are investigated. Because of the 
current clinical interest, this thesis focuses on image based dosimetry of 177Lu-
DOTATATE treatments. Despite the long history of dosimetry studies and recent 
promising clinical results, the availability of clinical dosimetry software for radionuclide 
therapy is poor and methods are badly standardised. Therefore, topics presented in this 
thesis have demand in clinical practice and are scientifically interesting especially within 
the field of medical physics. 
 
1.1 Why do dosimetry? 
 
The most important motivation for radionuclide dosimetry is to predict response and 
toxicity of the treatment. The evidence base for the use of internal dosimetry in clinical 
practice is reviewed by Stigari et al. [14]. The review included 92 radiotherapy dosimetry 
and dose-effect correlation studies found in PubMed. Even though the selected studies 
were rated to moderate or low clinical relevance categories, the evidence implies a 
correlation between delivered absorbed dose and the response and toxicity. Therefore, 
Stigari et al. concluded that dosimetry-based personalised treatments would improve 
outcome and increase survival.   
 
Probably due to the high complexity and uncertainty of internal emitter dosimetry only 
few studies report dose-responses. With a blood sample based method (not based on 
imaging) it has been found that absorbed dose to the red marrow predicts haematological 
toxicity better than the amount of injected activity of 131I labelled antibody [15]. In 
another study, fast clearance of 166Ho-1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetramethylene-phosphonic acid via kidney was found to induce renal toxicity with 
estimated kidney doses of 2.6-14 Gy [16]. In a recent study, nephrotoxicity after 177Lu-
DOTATATE treatment was found to be low, the mean absorbed dose to kidney being 
20.1 ± 4.9 Gy [17]. Tumour dose-responses have been reported only in two PRRT studies. 
In a subset of 13 patients treated with 90Y-[DOTA]-D-Phe1-Tyr3-octreotide (90Y-






dose to the tumour and the tumour size reduction [18]. The tumour dose estimates were 
based on quantitative 86Y-DOTATOC PET scans and the mean dose was 232 or 37 Gy 
for responding or non-responding tumours, respectively. In an other study, Ilan et al. 
found a similar tumour-response from 177Lu-DOTATATE treated patients [19]. The 
tumour response was estimated at the time the largest tumour reduction was observed. 
They used SPECT/CT images to quantify the activity in the tumours and thus only 
tumours larger than 2.2 cm were included in the study and the doses to tumour ranged 
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2 SPECT-based dosimetry of 177Lu-DOTATATE treatments 
 
2.1 Dosimetry workflow 
 
A generalised workflow of image based dosimetry in targeted radionuclide therapy (TRT) 
is shown in Figure 2-1. Briefly the process is as follows. A treatment radiopharmaceutical 
is introduced to a patient by an injection or infusion. Because the radiopharmaceutical is 
distributed heterogeneously within body by perfusion and kinetics of the 
radiopharmaceutical, kinetics of the radionuclide should be resolved temporally to get 
estimates of absorbed dose. This dynamic process can be followed, for example, by a 
series of single photon emission computed tomography (SPECT) acquisitions combined 
with computed tomography (CT). Based on the quantitative SPECT image 
reconstructions, the dose distribution can be estimated using dose calculation methods. 
 
 
Figure 2-1. Example of radionuclide therapy dosimetry workflow.  
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To be able to quantify and follow the activity in patients, radionuclides used in TRT are 
typically selected so that they emit, in addition to non-penetrating radiation ( - or  
particles) also x-rays or gamma radiation ( ), which can be detected outside the patient 
without interventions [20]. The patient is imaged using a gamma camera that produces 
projections from the activity distribution. 
 
Most of the activity quantification for dosimetry has been done using planar whole body 
scans. Although planar imaging method is relative fast and can easily cover the whole 
body, it lacks depth information and thus cannot separate overlapping organs from each 
other. In recent years, developments in image reconstruction compensation methods, 
hybrid SPECT/CT imaging systems and available computation power have made SPECT 
possible for daily practice [21, 22]. Combining SPECT imaging with CT, the 3D activity 
distribution can be measured and localised from the patient with a spatial resolution of 
approximately 1 cm or better. 
 
Because the radiopharmaceutical distribution changes over time in the patient, the activity 
distribution is assessed using serial quantitative SPECT/CT scans. Ideally, the whole 
but absorption, metabolism and excretion can take days and thus continuously repeated 
whole-body acquisitions with SPECT are not practically feasible. The sufficient number 
of SPECT/CT scans required for reliable sampling of time-activity curves (TACs) 
depends on the kinetics of the radiopharmaceutical. For example in the case of the 177Lu-
DOTATATE treatments, three or four acquisition time points have been shown to be 
clinically adequate for TAC measurements, starting from 1 hour and ending at around 
168 hours or later after the treatment injection [23]. 
 
For dosimetry purposes, the total number of radioactive decays is of interest, because it 
is proportional to the emitted energy by the radionuclide. The total number of decays 
within a volume equals the area under the TAC, which can be solved by integration and 
is referred as time integrated activity curve (TIAC) or cumulated activity. Mostly because 
of practical reasons, the true TAC is sparsely sampled and thus integration of TAC is 
done numerically or analytically with the help of model fitting. Depending on the 
dosimetry method, TIACs are solved at the organ level or as in study IV, the TIACs are 
calculated for each image volume element (voxel) separately.  
 
The aim of dosimetry is to obtain absorbed dose estimates from the target or critical 
organs. For that, the calculated TIAC values should be transformed into absorbed dose 
distributions. Probably the most widely used software for this is the OLINDA/EXM 
(OLINDA) that computes absorbed doses in standardised anatomic geometries 
(anthropomorphic digital phantoms) using pre-calculated conversion factors and organ 
average TIACs [24]. OLINDA was originally developed for risk assessment of 
internalised radionuclides and its use for patient specific dosimetry has been criticised 
[25, 26].  
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Heterogeneity of activity distribution can be taken into account by carrying out dose 
calculation using smaller volume elements instead of the organ averages. One obvious 
idea is to do dose calculations at the voxel level. There are numerous ways to do this, but 
mostly voxel level dose calculation methods can be categorised into the following three 
method types. The first and easiest absorbed dose calculation method is to assume that all 
the relevant radiation is absorbed locally and thus the total number of decays (TIAC) to 
dose conversion is just a multiplication with a dose conversion factor (DCF). The 
conversion method is simple to implement and fast to perform, but it does not take into 
account the cross-irradiation between voxels. The second calculation method is based on 
dose point kernels (DPK) that represent absorbed dose distribution as a function of 
distance from a point source. The TIAC image can be transformed to a dose distribution 
by convolving the image with a DPK. This method is also relatively fast, but needs special 
software to carry out the convolution. Other disadvantages are that DPK is voxel size-
dependent and it should be pre-calculated for all materials separately in the investigated 
volume. Because the DPK method is restricted to one material, it cannot take into account 
tissue inhomogeneity and artefacts can occur at the boundaries of different tissue 
densities. The third method is Monte Carlo (MC) simulation that is considered to be the 
most accurate method available. In MC simulations, numerous random particle tracks are 
simulated utilising detailed interaction libraries for the radiation type and tissue in 
question. There are several different MC simulation packages available. However, none 
has wide clinical acceptance for radionuclide dosimetry, because simulations are time 
consuming, dependent on many parameters and cumbersome to set up. 
 
In one part of this study, a hybrid dose calculation method that combines DCF and MC 
calculation methods is investigated for radionuclide therapy dosimetry. In the case of 
177Lu, mostly DCF method or OLINDA software has been used and both have their 
advantages and disadvantages. As mentioned earlier, the DCF does not take cross-
irradiation into account and could lead to dose underestimations due to gamma radiation 
yield from 177Lu. With OLINDA, absorbed dose estimates are based on organ averages, 
standardised geometries and homogeneous distributions and thus it cannot offer patient 




Lutetium-177 (177Lu) is an unstable radioisotope of the 71st element in the periodic table, 
lutetium. Because of its relatively short half-life (6.6 d), it is not naturally abundant and 
for medical use, it is produced in nuclear reactors irradiating 176Lu or ytterbium-176 
(176Yb) with neutrons: 




 , (2) 
 
respectively. All 177Lu used in this study was produced by Advanced Accelerator 
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Applications (AAA, Saint-Genis-Pouilly, France) through the direct method (Eq. 1). The 
direct method yields an end product with 176Lu, 177Lu and a small amount of long lived 
177mLu isotope. However, the portion of 177mLu has been reported to be less than 0.05% 
of the total activity and the contribution to absorbed dose calculations is negligible [27]. 
On the other hand, the indirect method (Eq. 2) requires complicated radiochemical 
separation process, but yields high specific activity and high radionuclide purity [28]. 
 
177Lu disintegrates by - decay to the ground state and to three different excitation levels 
of hafnium-177 (177Hf), the maximum released energy being 498.3 keV [29]. In Figure 
2-2, the decay scheme of 177Lu radionuclide with the main decays paths are shown. In 
addition to - particles, the decay process produces small amounts of x-rays, Auger and 
conversion electrons. The de-excitation of 177Hf emits several gamma rays ( ) with 
different energy. The gamma transitions of 113 keV and 208 keV being the most 
abundant, emitting 6.2 and 10.38 photons per 100 decays, respectively. These gamma 
energies are important for image based dosimetry and diagnostic imaging, because they 
are intensive enough for imaging and the energies are suitable for detection with a gamma 
camera. On the other hand, the emitted - particles are therapeutically effective, having a 
short mean range of 0.7 mm in soft tissue. The - particles deliver energy to relatively 
small volumes, therefore sparing the healthy tissues surrounding tumours, but beta 









Figure 2-2. Simplified - decay scheme of 177Lu radionuclide. Gamma emission 
probabilities of two transitions ( 3,1 and 1,0), used for scintillation imaging, are shown. 
The decay scheme is based on data from Laboratoire National Henri Becquerel, available 
at www.nucleide.org [31]. 
 
2.3 177Lu-octreotate (177Lu-DOTATATE) 
 
In this thesis, experiments focus on dosimetry of 177Lu-[DOTA0,Tyr3]-octreotate (177Lu-
DOTATATE, Lutathera®, AAA) radiopharmaceutical. Octreotate is one of many 
somatostatin analogues used in nuclear medicine [32]. The radiolabelled complex of 
octreotate,177Lu-DOTATATE, has shown to bind to somatostatin receptor expressing 
tissues [33], especially it has a high affinity to somatostatin subtype 2 receptors [34]. In 
general, 177Lu-DOTATATE treatment is well tolerated and has low and acceptable 
toxicity profile [12, 17, 35]. The first 177Lu-DOTATATE experimental treatments on 
humans were carried out over ten years ago [11], but after that, numerous clinical 
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2.4 Available internal dosimetry software 
 
There are several dosimetry packages published for radionuclide therapy, which will be 
briefly reviewed here. As mentioned earlier, OLINDA/EXM is the most widely used 
dosimetry software available, although it was originally intended for radiation safety 
calculations rather than clinical internal radiation dosimetry per se [24]. OLINDA/EXM 
is based on pre-calculated radiation absorbed fractions (S) for the ten whole-body 
phantoms representing reference adults, children, and pregnant women. OLINDA/EXM 
has a multi-exponential fitting and integration subprogram (EXM) for organ average 
accumulated activity calculations, but no image reconstruction or VOI analysis tools. 
There are at least two separate programs, SPRIND [36] and ULMDOS [37], which 
provide the missing data analysis tools for OLINDA/EXM. Because the dose calculation 
is based on fixed S factors, individual variations in organ shapes and positions cannot be 
taken into account. OLINDA/EXM allows the user to scale absorbed doses for patient-
specific organ masses, but the scaling affects only the self-irradiation dose component. A 
comparison study between OLINDA/EXM and full Monte Carlo dosimetry method using 
patient specific geometry (CT data) found a difference of 26% in mean organ doses for 
simulated 131I radionuclide distributions, even when the organ mass correction was 
applied in OLINDA/EXM calculations [38]. For tumour dose estimations, 
OLINDA/EXM uses spherical models which are treated as completely isolated objects 
and cross-irradiation dose is completely neglected. 
 
In addition to OLINDA/EXM, several research groups have published their own 
dosimetry packages. The most recent one is called Lundadose [39], which provides 
versatile absorbed dose calculation and analysis tools for SPECT and planar data. A good 
overview of other available software is given in a paper by Grimes et al. [40], where they 
also present JADA dosimetry software. Gamma camera vendors and healthcare 
companies have also published commercially available dosimetry software (Table 2-1). 
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Table 2-1. Commercially available dosimetry software for radionuclide therapies. 
Name of the software 
software Company name Features 
Dosimetry toolkit GE Healthcare 
Quantitative reconstruction 
and resident time 
calculations for OLINDA 
DOSEFX Comecer TAC analysis, fitting and dose calculations 
Simplicit90Y Mirada in co-operation with BTG 
For 90Y SIRT therapy,  
CE mark certificated 
Stratos Philips Healthcare 
Full dosimetry package, 
research use only. Also 
voxel level calculations 
Automated Internal 
Dosimetry Research Tool Siemens Healthineers 
Full 177Lu specific 
dosimetry package, 
research use only 
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3 Aims of the study 
 
The aim of this thesis was to develop and validate patient specific dosimetry software for 
radionuclide therapies, focusing on neuroendocrine tumour treatments with 177Lu-
DOTATATE. Studies were designed to cover all the main steps of radionuclide therapy 
dosimetry, namely: quantification, kinetic analysis and dose calculations. In addition, the 
developed dosimetry workflow and software was compared to OLINDA/EXM.  
 
Studies in this thesis were designed to: 
 
I Evaluate the effect of SPECT reconstruction compensation methods to 
quantification accuracy of the 177Lu radionuclide 
 
II Study absorbed dose characteristics of 177Lu in tissue and validate fast 
absorbed dose calculation method for the dosimetry software 
 
III Compare the small volume method and the mean kidney dose calculation 
method with each other 
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4 Materials and methods 
 
In the following section, basic dosimetry quantities and used methods are introduced. The 
content of the section follows the same logical progression as the original articles. 
  
4.1 SPECT based quantification of 177Lu 
 
The aim of quantification is to exactly quantify the concentration of radioactivity within 
a given volume in absolute units, for example kBq/cm3. Unfortunately, the SPECT 
imaging process is compromised by photon attenuation, photon scatter, and the detector 
CT is not 
inherently quantitative. These image deteriorating effects can be partly compensated 
during properly optimised iterative image reconstruction and images proportional to the 
amount of activity can be produced. More comprehensive reviews of compensation 
methods are published, for example, by Ritt et al. [22]. 
 
For radionuclide therapy dosimetry, the activity quantification is essential, because 
activity is proportional to dose rate at a given time point. In this study, we only considered 
the SPECT/CT methods for quantifying 177Lu activity distributions, but it should be noted 
that planar imaging has also been frequently used. However, it has been shown in 
simulation and patient studies that a solely planar imaging method is prone to overlap and 
attenuation correction problems and the TAC estimate accuracy is worse than with a 
SPECT protocol [41, 42]. The blood activity 177Lu levels can also be measured from blood 
samples as it is done in bone marrow dosimetry [43], but that method was not used in this 
thesis. 
 
4.1.1 SPECT imaging protocol 
 
SPECT acquisition of 177Lu distribution within patients and phantoms were carried out 
using a two headed Siemens Symbia T2 gamma camera (Siemens Healthineers, Erlangen, 
Germany) combined with a two slice CT. The SPECT imaging protocol was the 
following. One field of view SPECT scans were acquired in noncircular step and shoot 
mode, to produce 64 projection of the source. The time per projection was 20 s and it took 
approximately 15 minutes to complete the scan. The projections were acquired into 128 
x 128 matrix producing the pixel size of 4.79 mm at the detector plane. The higher 208 
keV photon peak was acquired using 20% width energy window (range: 187.3  228.8 
keV) associated with an upper (228.8  270.4) and a lower (145.6  187.2 keV) scatter 
energy windows. Medium energy general purpose collimators (MEGP) were used to 
optimize camera sensitivity and decrease the collimator septal penetration. 
 
The 177Lu SPECT imaging protocol used in this thesis was similar to other protocols 
reported in the literature [44-46] and was generally consistent with the guidelines of 
European Association of Nuclear Medicine (EANM) and Committee on Medical Internal 
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4.1.2 SPECT image reconstruction 
 
Two implementations of an ordered subset expectation maximisation (OSEM) algorithm 
[48], Flash3D (Siemens, Germany, Erlangen) [49] and HybridRecon (HERMES Medical 
Solutions, Stockholm, Sweden) [50] were used for SPECT image reconstructions. The 
latter was further implemented for the new dosimetry software (study IV). Both 
reconstruction software packages provide compensations for photon attenuation (AC) 
[51], photon scatter (SC) and resolution recovery (RR, also known as collimator-detector 
response CDR) [52]. The fundamental difference between the implementations lies in the 
scatter correction. In Flash3D, a triple energy window (TEW) scatter compensation 
method is used, where the scatter portion from the detected primary photons is estimated 
using a weighted ratio of photons detected in the upper and lower energy windows [53, 
54]. On the other hand, HybridRecon does scatter estimations based on fast MC 
distribution [55]. The number of iterations and subsets varied between studies and are 
shown in Table 4-2. In Flash3D a post-reconstruction Gaussian filter of 8.4 mm full width 
at half maximum (FWHM) was also applied. PVE correction other than CDR were not 
used in any study. All images were reconstructed into isotropic (4.79×4.79×4.79 mm3) 
voxels in 128×128×128 matrix. 
 
Table 4-2. SPECT image reconstruction parameters in different studies. 
Study OSEM Algorithm Iterations Subsets Post-filtering 
I HybridRecon 15 16 - 
II HybridRecon 15 8 - 
III Flash3D 8 4 8.4mm FWHM Gaussian 
IV HybridRecon 8 16 - 
Flash3D 8 4 8.4mm FWHM Gaussian 
 
Image reconstruction produces images that represent the distribution of activity averaged 
over the acquisition. The intensity in voxels is, with some limitations, proportional to 
activity and is usually represented in unit of counts (c) or counts per second (cps), if 
normalised by the projection acquisition time. 
 
4.1.3 CT imaging protocol and reconstruction 
 
SPECT acquisition was always followed by a CT scan that covere
view. The scan time of CT was about 37 seconds with the tube voltage of 130 kV. 
Automated Exposure Control and dose modulation options of CARE Dose 4D (Siemens 
Healthineers, Germany, Erlangen) were used with the quality reference tube current-time 
product of 85 mAs. A mean volume CT dose index (CTDIvol) was 10.8 mGy. The CT 
data was reconstructed to 512 × 512 matrix producing axial pixel size of 0.98 × 0.98 mm 
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The CT images were reconstructed at acquisition workstations using two different 
reconstruction kernels. A sharp (B35) kernel image was used for localisation and kidney 
VOI delineation. For the attenuation map, another reconstruction was done using a 
smoother kernel (B08s) and the CT voxel values presented in Hounsfield units (HU) were 
converted to linear attenuation coefficients using a bilinear conversion equation [51]. The 
attenuation map was further used during the SPECT reconstruction for photon attenuation 
and scatter compensations. 
 
4.1.4 Cross-calibration of imaging system 
 
To be able to quantify activities from reconstructed SPECT images, the system sensitivity 
and the relation to the absolute activity should be resolved. Cross-calibration between the 
SPECT/CT imaging system and the dose calibrator can be done using a calibration 
phantom filled uniformly with a known amount of 177Lu activity (Figure 4-3). The 
phantom is scanned with the SPECT/CT system and reconstructed. A calibration 
coefficient vol in cps/MBq), that is the ratio of reconstructed counts in the active source 
and the total activity in the phantom, can then be determined from the phantom image. 
With the vol coefficient, the reconstructed SPECT image voxel values can be converted 
into activity concentrations (in MBq/cm3) by simple multiplication. 
 
In studies presented in this thesis, two different calibration phantoms were used to obtain 
vol. The phantom 1 was a 0.5 litre bottle with 234.6 MBq of 177Lu activity submerged 
in a water filled Jaszczak phantom (Studies I and IV). The phantom 2 was a modified 
Alderson radiation therapy phantom with a source cylinder insert (radius = 3.3 cm, height 
= 8.0 cm and activity = 53 MBq) in abdomen area (Studies III and IV). The cross-
calibration method is in line with the available guidelines [45, 47]. In addition, the 
vol was followed with the phantom 2, after 177Lu-DOTATATE treatments 
were begun at the HUCH. The SPECT/CT system was found to be stable (unpublished 
quality assurance data). Similar calibration method have also been shown to be 
reproducible in a multicentre study [56].  
 
 




Figure 4-3 Images of the phantoms used for cross-calibration of the SPECT/CT system. 
(Top row) A Jaszczak phantom with a 177Lu filled plastic bottle insert and (bottom row) 
an anthropomorphic phantom including a 177Lu filled cylindrical container. In the middle 
and right columns, transversal and coronal SPECT images overlaid with CT images are 
also shown from both phantoms. 
 
4.1.5 Dose calibrator activity measurements 
 
All activity inserted in the phantoms or infused to patients were measured using a dose 
followed daily by 57Co constancy test, biannually by linearity measurements using a 99mTc 
source and annually by accuracy measurements using 133Ba source. In addition, the dose 
177Lu 
(Polatom, Otwock, Poland). 
 
4.1.6 Quantification accuracy of 177Lu using SPECT/CT 
 
In study I, the effect of reconstruction compensation methods to quantification accuracy 
of 177Lu was investigated. This study was conducted using a modified anthropomorphic 
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thorax phantom with nine spherical inserts. Six of the inserts were part of the NEMA 
image quality phantom with volumes ranging from 0.4 to 26.1 ml and three were in-house 
made with volumes of 30.3, 30.3 and 104.4 ml. The inserts were filled with 177Lu solution 
and placed into the phantom with background activity. From reconstructed images, a 
concentration recovery coefficient (cRC) was calculated for each insert 
 
  4.3 
   
where Rinsert is the count density within the VOI, Vinsert vol 
is the system calibration factor and the Cinsert is the true concentration in the insert. VOIs 
were drawn on the CT image based on physical boundaries of the inserts and then 
transferred to the corresponding SPECT image. 
 
The study also included patient SPECT/CT data from ten 177Lu-DOTATATE treatments 
(see Table 4-3). The data were acquired at three time points at 24 , 74 and 168 h post-
treatment. Anatomical kidney VOIs were delineated based on CT images at each time 
point and the activity in the kidneys were estimated from SPECT images for each time 
point. A mono-exponential function (y(t) = Ae- ) was fitted to kidney time-activity series 
for TAC estimation. The effective half-life ( ) and absorbed dose to the kidneys 
were estimated separately for each patient and each reconstruction separately. 
 
4.2 Absorbed dose 
 
The basic physical quantity to study ionisation radiation effects on biological tissue is the 
absorbed dose, D. The absorbed dose is defined as the mean energy imparted, , into a 
volume of tissue with the mass, , that is 
 
  (4) 
 
The unit of measure for absorbed dose is Jkg-1 in base units and in International System 
of Units it is known as grey (Gy). By taking into account the target-source relationship 
and radiation nuclide characteristics, equation (4) can be extended for internal emitters at 
the voxel level as follows. The absorbed dose to target voxel  due to radioactivity 
located in source voxel  is expressed as 
  (5) 
 
where  is total number of nuclear decays in the source voxel ,  and  are the 
energy and frequency of each radiation type i, the fraction of absorbed energy 
  from the source to the target from the each radiation type and is the 
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mass of the target voxel. Equation (5) is known as the MIRD formalism [57], which 
contains the essentials of internal dose calculations. Equation (5) can be separated into 
two parts: i)  that depends on the kinetics of the activity and ii) 
 that depends on the physical properties of media, 
geometry and decaying radionuclide. The latter is also known as the absorbed fraction. 
 
4.2.1 Voxel based absorbed dose calculations of 177Lu 
 
In mean organ dosimetry calculations (OLINDA type software), the S factor for  
particles is typically considered to be 1 for self-irradiation case , and zero for 
cross-irradiation . This is due to the fact that the ranges of  particles used in 
TRT are relative short compared to organ sizes and their distances from each other, thus 
the cross-irradiation is considered negligible. In case of 177Lu, the contribution of photon 
cross-irradiation dose to total dose is also considered to be within a few percentages and 
typically omitted from the absorbed dose calculations [23]. However, when carrying out 
voxel level dosimetry calculations, voxel sizes and therefore also distances are at the 
ranges from millimetres to centimetres and thus S factor for cross-irradiation could be 
notably larger than zero. 
 
In study II, the radiation characteristics of 177Lu and relevance of cross-irradiation dose 
in voxel level dosimetry is investigated. In addition, a semi-MC absorbed dose calculation 
method (sMC) for 177Lu is introduced. The sMC assumes that electrons are absorbed 
locally (DCF method) and photons are modelled using an accelerated MC-simulation 
method based on delta-scattering [58]. The idea is to omit computationally troublesome 
electron simulations, but still include potentially important components of photon dose to 
the dose calculations. The photon interactions are simulated using cross-section tables 
defined by Berger et al. [59] and all materials are assumed to be water with varying 
density based on the density map (converted CT image). Simulations of photons are 
traced until their energy drops below Eabs = 15 keV, after which they are assumed to be 
absorbed in their current voxel. All the secondary particles produced by photons are 
assumed to be locally absorbed. In study II, sMC method is also compared to a full Monte 
Carlo dose method (vxlPen) and validity of sMC assumptions are tested. 
 
In study II, cross-irradiation dose was studied using a simple digital kidney phantom. An 
ellipsoidal kidney model (axis sizes of x = y = 7 cm and z = 12 cm) filled with a 
homogeneous 177Lu activity was simulated in a homogeneous soft tissue media. The 
kidney to background activity concentration ratio varied from 1:1 to 20:1 between the 
simulations. The photon cross-irradiation dose between background and the kidney was 
studied by comparing absorbed dose calculations with and without photon simulations in 
the kidney model. In the second part of the study, the amount of cross-irradiation to an 
identical target kidney volume was recorded at nine different distances from the surface 
of the active kidney.  
 
The comparison between a full MC dosimetry implementation vxlPen and sMC was 
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carried out using a digital XCAT phantom [60]. XCAT is a detailed whole-body digital 
phantom based on non-uniform rational basis spline (NURBS) defined anatomy. XCAT 
was simulated with default male settings and average organ activities measured from ten 
randomly selected 177Lu-DOTATATE treated patients used in study I. The phantom was 
forward projected to produce SPECT data using in-house MC based projector [61]. From 
the projections, twenty noise realisations were created and reconstructed using 
HybridRecon. From the images, the absorbed doses calculations were done using vxlPen 
and sMC and the differences of 3D dose distribution were evaluated. 
 
4.3 177Lu-DOTATATE treatment protocol at Comprehensive Cancer Center 
 
In the Helsinki University Central Hospital (HUCH) Comprehensive Cancer Center, 
patients are typically treated with four cycles of 177Lu-DOTATATE infusion at eight-
week intervals. Patients receive a kidney-protective amino acid infusion (Vamin 14 g 
N/I®) that starts half an hour before the treatment infusion and is continued up to eight 
hours. The treatment infusion takes 30 minutes to complete. Before and between 
treatment cycles, possible radiotoxicity (haematocixity) and renal toxicity unrelated to 
PRRT is followed with blood samples. Patients are released from the hospital one day 
after the treatment. The decision in order to proceed with follow-up treatments is made 
after the completion of four treatment cycles if the mean kidney absorbed dose does not 
reach 27 Gy. 
 
Typical administered activity per treatment is 7.4 GBq of 177Lu, which sums up to the 
total activity of 29.6 GBq from four treatments. The activity was lowered 75% or 50% 
for patients who had any signs of bone marrow toxicity. Other reasons for lower treatment 
activity were older age, previous chemotherapy, diabetes, hypertension, fragility and any 
combination of these.  
 
ral 
publications and is in line with practical guidelines [62], a long amino acid infusion being 
an exception. Commonly, up to four hour infusion is reported [23, 63-65]. Reasoning for 
the longer amino acid infusion protocol is the observation in Sandström et al. article [43], 
that the activity in blood decreases fast within the first day and thus amino acid infusion 
was prolonged as long as practically feasible. Amino acid infusion causes nausea, but it 
can be treated and in general infusions have been well tolerated. 
 
4.3.1 Patient data 
 
Twenty-four consecutive patients with metastatic NETs (WHO grade G1 or G2) treated 
with 177Lu-DOTATATE were included in the study. All the treatments were conducted 
in the Department of Radiotherapy, Comprehensive Cancer Center, HUCH, from 
February 2011 to August 2013. All patients had four treatment cycles. From the entire 
patient sample, smaller subgroups were selected for studies I and IV and the whole data 
were analysed in study III. The characteristics of patient data for each study and sampling 
criteria are shown in Table 4-3. 
 
 




Table 4-3. Number of patients and analysed treatments in studies I, III and IV. The mean 
infused activities and patient selection criteria are also listed.  











I 10* 1 6.8 (3.7  8.1) Randomly from study III 
     
III 24 4 7.1 (3.3  8.79) 
Consecutive 177Lu-
DOTATATE treatments 
from February 2011 to 
August 2013 
     
IV 6* 2 
4.3 (3.7  6.2) Patients with reduced and 
normal treatment activities 
from study III 7.7 (6.0  8.3) 
*Subgroup of study III patients  
 
4.3.2 Dosimetry protocol in HUCH 
 
Imaging for kidney dosimetry was carried out using SPECT/CT at 24, 72 and 168 hour 
after the treatment infusion. Some of the patients had also 1 hour post-treatment imaging 
time point, but it was not used for dosimetry. From the reconstructed images, the activity 
within both kidneys was measured using two different VOI-analysis method (see below). 
A mono-exponential or bi-exponential function was fitted to time-activity data and 
absorbed doses to both kidneys were calculated using a reference adult (female or male) 
phantom in OLINDA [24] software. The absorbed dose was scaled by the mass of kidney 
that was estimated from delineated volume.  
 
4.3.3 Mean kidney dose 
 
Mean absorbed dose to kidney was estimated delineating whole left and right kidney 
volumes (WKVs) from each of the three CT images separately. Delineation was based on 
observed physical boundary of the organ. The mean activity at certain time point was 
measured from corresponding calibrated SPECT images using the VOIs. Mono-
exponential TAC fits and the mean absorbed doses were calculated using OLINDA/EXM 
for both kidneys separately. 
 
4.3.4 Small VOI method 
 
Approximation of maximum absorbed dose was measured using a spherical VOI with 
volume of 4 cm3. The small VOI (SV) was positioned on the maximum activity region of 
the lateral kidney cortex and medulla on the three SPECTs at different time points. Mean 
activity within SVs were scaled to correspond the whole kidney volume. Scaled activities 
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were used to calculate mean estimated maximum absorbed dose to kidneys using 
OLINDA software. 
 
4.3.5 Effect of activity sampling method to kidney dosimetry  
 
In study III, the differences between WKV and SV activity sampling methods were 
studied. Rationale for comparison was that the both methods, WKV and SV, are used in 
published studies and the comparison gives insights of heterogeneity of 177Lu-
DOTATATE uptake in kidneys. Twenty-four consecutive patients with four treatment 
cycles were analysed using both methods and estimated absorbed doses and effective 
half-times (Teff) were compared. 
 
In addition, a less demanding imaging protocol for dosimetry was introduced.  The fast 
kidney dose (FKD) method is based on conversion coefficient (k) determined from 
absorbed doses from the patients, effective half-life (T½,eff) determined by mono-
exponential fit to 24 and 168 h acquisition data and patient specific kidney volumes (Vk). 
The mean absorbed dose to kidney in FKD method was calculated using following 
equations: 
 
  (6) 
 
and 
 , (7) 
 
where k = 0.021 mGy/g/MBq s is a conversion coefficient, T½ is the effective half-life (in 
hours) estimated from the observed kidney counts in the SPECT images C24 and C168 at 
24 and 168 h acquisition time points, respectively and Vk is the mass of the delineated 
kidney volume assuming density being 1.00 g/cm3. The FKD method was also compared 
to WKV and SV methods in study III. 
 
4.4 Voxel level absorbed dose calculation method: HIRD 
 
As a part of this thesis, a voxel level dosimetry software called HERMES internal 
radiation dose (HIRD) was developed. Software was developed in collaboration with 
HERMES Medical Solutions (Stockholm, Sweden) and HUCH Comprehensive Cancer 
Center. Software was developed to run under HERMES patient database application Gold 
(HERMES, Stockholm, Sweden). Next, the essential parts of voxel level dosimetry 
methods implemented in HIRD are presented, but auxiliary functionalities such as image 
co-registration algorithms, delineation tools and motion correction methods are outside 
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The HIRD was developed to include all the necessary post-processing step of acquired 
data to perform voxel-level dosimetry for radionuclide therapies. In this study, 177Lu 
radionuclide and 177Lu-DOTATATE treatment data are employed because of their 
clinical importance. 
 
4.4.1 Voxel level dosimetry workflow  
 
The workflow of the HIRD software is shown in Figure 4-4. In practice, the workflow is 
briefly as follows. The software is launched with input of all the necessary SPECT/CT 
datasets for dose calculation. At the first step, reconstruction parameters are chosen and 
the SPECT projection data are visualized for possible motion during imaging. Then, co-
registration of SPECT and CT data is verified by the user and reconstruction is carried 
out for each SPECT/CT datasets separately. If misalignment between SPECT and CT 
data is noticed, it should be corrected to prevent attenuation and scatter correction 
artefacts. The correction can be done manually or using mutual information based 
automatic co-registration algorithm. After the reconstructions, CT images from different 
time points are registered to a reference CT image space. The registration can again be 
done manually or with help of automatic rigid co-registration algorithm. After satisfactory 








Figure 4-4. Dosimetry workflow implemented in HIRD. The workflow is as follows: A) 
Program is initiated with series of SPECT/CT datasets. B) Quality verification of SPECT 
data and alignment with CT data, motion correction, and reconstruction. C) Co-
registration of CT images between different time points to same reference space. D) TAC 
fitting and integration voxel by voxel. E) Result overview, visualisation and saving. 
 
 




Figure 4-5 Example TAC and illustration of TIAC calculation method implemented within 
HIRD. Black circles represent SPECT/CT acquisition time points. Area under the curve 
is divided into grey and polka dot shaded depending on whether the integral is defined 
analytically or numerically using trapezoid rule, respectively. Tphys is half-life of the 
radionuclide and Teff is effective half-life analytically estimated from the last two time 
points. 
 
At this point, all SPECT and CT images should be aligned in the same reference space 
(that is, corresponding SPECT voxels at each time point represent the same volumes) and 
TAC analysis can be done. TAC analysis and integration is done in two different ways 
depending on how many SPECT/CT data sets the software is launched with. If HIRD is 
launched with more than one dataset, TAC and TIAC are estimated in three parts. The 
first part of TAC is extrapolated backwards, from the first acquisition time point to the 
treatment infusion, using a mono-exponential function with the physical half-life of the 
radionuclide (Tphys). The tail of the TAC curve is extrapolated with an exponential 
function with an effective half-life (Teff) calculated from last two acquisition time points. 
Due to noise in voxel level TACs, Teff is constrained to be equal or smaller than Tphys. 
Then, TIAC is calculated analytically at extrapolation parts and using the trapezoidal rule 
between acquisition points (Figure 4-5). If only one dataset is used as input, TAC is 
modelled only using a mono-exponential function with the Tphys of used radionuclide. All 
the TAC estimates and TIAC calculations are done for each voxel separately. After 
TIACs are calculated, absorbed dose calculations are done using sMC method that was 
earlier introduced in study II. 
 
The workflow of HIRD ends at the step where the user can view, analyse and save 
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4.4.2 Testing HIRD and clinical utility 
 
In study IV, the validity of voxel level dose calculation and clinical utility of the HIRD 
software for kidney dosimetry were tested. A digital XCAT phantom with a model of 50 
ml liver tumour was created to simulate 177Lu activity distributions in a 177Lu-
DOTATATE treated patient at 1, 24, 74, and 168 h post-treatment. Kinetics of 177Lu-
DOTATATE was modelled using a mono-exponential function, the parameters of which 
were averaged from ten randomly selected patients. SPECT projection data were 
simulated from the XCAT phantom using an in-house developed projector [61]. The 
density map of the XCAT phantom was converted to a CT image using inverted bi-linear 
conversion from HU units to density. From simulated SPECT/CT datasets photon and 
electron absorbed doses at the voxel level were separately calculated using HIRD. Mean 
absorbed dose to spleen, kidneys and to a liver tumour produced by electrons were 
compared to the analytically calculated reference organ doses (Dref,electron). For Dref,electron 
calculation, photon contribution was neglected so that Dref,electron was equal to the sum of 
kinetic energy of electrons emitted by 177Lu. Dref,electron was calculates as follows: 
 
 , (8) 
   
where Teff is effective half-life of the organ, A0 is activity in voxels at that organ at time 
of injection and 2.14  mGy / MBq is activity to absorbed dose conversion 
coefficient derived from the electron spectrum emitted by 177Lu. 
 
The HIRD workflow was also tested using clinical patient data. A subgroup of six patients 
with high and low activity 177Lu-DOTATATE treatments were selected from the study 
III patient sample. Patients were re-analysed using the HIRD software and mean 









5.1 Quantification accuracy of 177Lu 
 
In study I, calibration of the SPECT/CT system was successfully carried out using the 
calibration phantom 1. Quantification accuracy of 177Lu radionuclide using SPECT/CT 
imaging was measured using cRC (Equation 4.3) and results are summarised in Table 5-
4. Recovery curves for all three studied methods are shown in Figure 5-6. The 
quantification accuracy improves as more compensation methods are used and the most 
accurate results were achieved using AC-SC-CDR compensation methods. It should be 
noted that full activity recovery (cRC = 1) for any insert could not be achieved, which 
can partly be explained with partial volume effect. The inserts were delineated according 
to the physical boundaries from CT image and due to poorer resolution of SPECT some 
activity spills out from delineated volume. Another notable point is that including MC-
simulation based SC method improved quantification accuracy especially for smaller 
sources. 
 
Table 5-4. Summary of quantification accuracy results of study I. Q1-Q9 are the inserts 
inside an anthropomorphic phantom.  
Insert label Q9 Q8 Q7 Q6 Q5 Q4 Q3 Q2 Q1 
Volume (cm3) 0.4 1.2 2.6 5.5 10.8 26.1 30.3 30.3 104.4 
Diameter (cm) 0.9 1.3 1.7 2.2 2.7 3.7 3.9 3.9 5.8 
Activity (MBq) 0.52 1.24 2.69 5.80 11.90 27.16 30.43 31.15 105.18 
          
 Measured activity (MBq) 
AC 0.05 0.17 0.60 1.73 4.78 14.18 13.78 14.72 66.24 
AC-CDR 0.09 0.42 1.38 3.05 7.02 18.23 21.04 19.77 85.44 
AC-SC-CDR 0.16 0.60 1.89 4.08 8.97 23.16 25.90 23.35 89.88 
          
 cRC  
AC 0.10 0.13 0.22 0.30 0.40 0.52 0.45 0.47 0.63 
AC-CDR 0.18 0.34 0.51 0.53 0.59 0.67 0.69 0.63 0.81 










Figure 5-6. Quantification accuracy of 177Lu using SPECT/CT. Figure represent cRC 
using three reconstruction compensation methods. Smaller volumes are less accurately 
quantified due to partial volume effect. 
 
From patient data, higher activities were also measured from kidneys with AC-SC-CDR 
method than AC or AC-CDR methods. In Figure 5-7, effective half-life estimates and 
calculated absorbed doses from patient data are shown using all three methods. AC-SC-










Figure 5-7 Box plots of effective half-life (above) and absorbed dose estimates (below) 
for right and left kidneys. The total number of patients was ten. The full triangles indicate 







There was only one patient case, where AC method produced higher absorbed doses than 
other methods. This was due to the high uptake in liver metastases, which spills in to the 
right kidney volume in AC reconstruction, but which was reduced in AC-CDR and AC-
SC-CDR reconstructions (Figure 5-8) 
 
 
Figure 5-8. Transversal CT and SPECT slices of a patient case with numerous metastases 
in liver. Grey and red areas represent right and left kidney volumes. With AC-CDR or 
AC-SC-CDR compensations spill in from liver to right kidney volume was reduced. 
 
5.2 Validation of sMC calculations method 
 
Electrons emitted by 177Lu can be assumed to absorb locally in voxel scales (~4 mm) that 
are currently used in SPECT imaging. This was shown in study II where absorbed dose 
produced by electrons was shown in DPK simulation to reduce down to 1% in the adjacent 
voxels compared to the source voxel. Using the ellipsoidal kidney models, the 
contribution of cross-irradiation to the target kidney was shown to be less than 1% when 
compared to the dose that kidney receives from self-irradiation, even when kidneys were 








Figure 5-9. Cross-irradiation dose between source and target kidney models as function 
of distance. Cross-fire dose on y-axis is relative to self-irradiation dose of the target 
kidney. Photon doses were simulated using sMC (full circle) and vxlPen (circle) codes 
and electron doses (triangle) with vxlPen code. 
 
On the other hand, when simulating a relatively high activity kidney model in semi-
infinite soft tissue material, it was found that photons could produce a significant increase 
in dose heterogeneity on the surrounding voxels (Table 5-5). For example, 5% increase 
in absorbed dose was observed up to 5.8 cm (~14 voxels) range from the face of the 
model, when kidney to background concentration was 1:20. This could be significant in 
cases where highly active tumour or metastases are located next to the organ of interest, 
such as in a patient case in study I (Figure 5-8). 
 
Fast voxel-level absorbed dose calculation method sMC produced very similar average 
absorbed doses to kidneys when compared with detailed MC simulations (vxlPen). 
Comparison was done using simulated SPECT data in XCAT phantom geometry. The 
percentage differences between the methods were -0.4% and -5% for electron and photon 
doses, respectively, sMC producing smaller doses. Even the photon dose difference was 
clear as seen from dose rate volume histograms in Figure 5-10, the average absorbed dose 







Table 5-5. Relative increase in absorbed dose due to photon cross-fire for five different 





From the kidney volume into the background 
 








0.2 1.0 1.8 2.6 3.4 4.2 5.0 5.8 6.6  
1:1 1.02 1.01 1.01 1.01 1.00 1.00 1.00 1.00 1.00  1.1 
2:1 1.03 1.02 1.01 1.01 1.01 1.01 1.01 1.00 1.00  1.05 
5:1 1.08 1.06 1.04 1.03 1.02 1.02 1.01 1.01 1.01  1.02 
10:1 1.17 1.11 1.07 1.06 1.04 1.04 1.03 1.02 1.02  1.01 
20:1 1.34 1.23 1.15 1.11 1.09 1.07 1.06 1.05 1.04  1.01 
 
The difference of the photon doses was further investigated by comparing electron and 
photon dose distribution separately using XCAT phantom. The biggest dose differences 
were observed in bone structures, which can partly be explained by the fact that sMC uses 
only water cross-sections for photon interaction modelling. 
 
 
Figure 5-10. DrVHs of left and right kidneys of XCAT phantom simulated using vxlPen 
(solid line) and sMC (dashed line). The upper row shows electron dose distributions and 






5.3 Mean kidney doses in patients using OLINDA/EXM 
 
Mean kidney dose and estimated maximum dose to kidneys were calculated using WKV 
and SV methods, respectively. A total of 96 treatments from 24 patients were analysed. 
The mean activity per treatment was 7.1 GBq for seventeen patients and the remaining 
seven patients, were treated with reduced activity due to clinical risk factors. The mean 
absorbed doses were 0.44 ± 0.15 Gy/GBq (range 0.22 1.05 Gy/GBq) and 0.74 ± 0.28 
Gy/GBq (range 0.36 1.92 Gy/GBq) for WKV and SV methods, respectively. The 
difference between the methods was found to be significant (p < 0.001), which implies 
heterogeneity in kidney absorbed doses. Despite the absorbed dose difference between 
the methods, the effective half-life was estimated to be 45.3 ± 5.9 hours (range 35.5 58.9 
hours) and 46.2 ± 5.6 hours (range 37.8 57.7 hours) using WKV and SV methods, 
respectively. The estimated absorbed doses and half-life times using WKV method are 
similar to those which were analysed in study I with HybridRecon and AC-SC-CDR 
compensation methods, where the mean absorbed dose was 0.44 Gy/GBq and Teff was 
44.3 hours from the subsample of 10 patients. 
 
Kidney toxicity as measured by serum creatinine levels was not observed in any patient 
during the two year follow up after the treatment. On the other hand, grade I 
hematological toxicity was observed in 12 patients.  
 
5.4 Voxel-level kidney dosimetry  
 
Implementation of sMC method to HIRD was tested using simulated SPECT/CT data 
from XCAT phantom. The dosimetry package successfully reconstructed and calculated 
doses from simulated data. Analytically calculated Dref,electron (Equation 8) from the 
original TACs and simulated DHIRD,electron and DHIRD,photon doses are shown in Table 5-6. 
The difference between doses were within 6 % in all studied organs. 
 
Table 5-6. Comparison of electron absorbed doses between HIRD (DHIRD,electron) and 
analytically calculated reference kidney doses (Dref,electron). Photon contribution to organ 
doses calculated using HIRD is also shown (DHIRD,photon). 
 Left Kidney Right Kidney Spleen Tumour 
Dref,electron 9.42 9.42 16.39 20.84 




6% 5% 0% 2% 
     
DHIRD,photon 0.56 0.49 0.67 0.67 
DHIRD,photon / DHIRD,Total 
(%) 








Patient kidney doses calculated with HIRD and OLINDA/EXM were compared using a 
relative Bland-Altman plot (Figure 5-11). The mean difference between doses was 2%, 
the OLINDA/EXM producing slightly higher average doses. However, HIRD produces 
higher doses at doses below 2 Gy. This can be partly explained by photon cross-irradiation 
dose that is taken into account in the voxel level dose calculations by HIRD and photon 
cross-irradiation from high uptake volumes (e.g. metastases) in vicinity of the kidneys. 
 
 
Figure 5-11. A relative Bland-Altman plot of kidney doses of OLINDA/EXM and HIRD. 
Doses to left (dot) and right (cross) kidneys are shown separately. The limits of agreement 
(dashed line), from -1.96SD to +1.96SD, were calculated for both kidneys together.  
 
Photon dose contribution from high 177Lu-DOTATATE tumour uptake was studied from 
a small number of patient cases. Figure 5-12 shows an example coronal CT image of a 
patient with relative low average kidney uptake but with high activity uptake in 
metastases next to the left kidney. The photon dose to left and right kidneys was 0.3 Gy 
(15% of total absorbed dose) and 0.2 Gy (9%), respectively. Part of the left kidney 









Figure 5-12. (Top) Coronal CT slices fused with electron and photon dose distributions 
from a patient case with a tumour mass next to left kidney. Ratio between photon and 
electron doses in kidney volumes is also visualised. (Below) Voxel level photon / electron 








In this thesis, radionuclide dosimetry methods were studied and voxel-level dosimetry 
software for radionuclide therapy was presented and validated. for kidney dosimetry after 
177Lu-DOTATATE treatment. Results of the original articles, included in this thesis, are 
discussed in more details in the corresponding papers. In this section, uncertainties in 
radionuclide dosimetry and other observations during software development are 
discussed. Discussion is concluded with future aspects of software development and 
implementations. 
 
6.1 Determinants of SPECT image based dosimetry accuracy 
 
SPECT image based dosimetry consists of five crucial steps, which are SPECT 
acquisition, quantitative image reconstruction, TAC analysis and integration, absorbed 
dose calculations and result analysis. Each of these steps can be dealt with separately, but 
in this thesis the last four steps were combined together to form a streamlined dosimetry 
software. The SPECT acquisition protocol used in this thesis was adopted from HUCH 
Comprehensive Cancer Center, where it was in used in clinical practice. Optimisation of 
acquisition protocol could have an impact on dosimetry accuracy, but due to practical 
reasons it was less emphasised in this thesis.  
 
There are a number of potential sources of bias and variance in determining absolute 
activities using SPECT imaging. After injection, the kinetics of the injected 
radiopharmaceutical is followed with a series of SPECT/CT acquisitions. Depending on 
kinetics of the pharmaceutical in question, acquisitions can extend over a week. From 
acquired sinograms, three dimensional activity distributions are reconstructed and activity 
is quantified. In study I, the quantification accuracy of different reconstruction 
compensation methods, measured with cRC, was found to be of 0.85 for spherical 177Lu 
sources with volumes larger than 25 ml (corresponding to a sphere with radius of 1.8 cm). 
For smaller sources quantification cannot be considered to be very reliable (Figure 5-6). 
Similar results have been reported also by other authors [44, 46, 66-68]. It is known that 
CDR compensation method enhances so called Gibbs ringing artefacts in reconstructed 
images [69]. Even though the CDR improves quantification, for voxel level dosimetry 
this can be problematic, because the artefact distorts activity distribution, which can lead 
to false absorbed dose distributions. An example of the ringing artefact can be seen in 
Figure 4-3, but it was however not observed in patient images (Figures 5-8 and 5-12). 
There have been efforts to reduce the effect of the artefact [70], but further studies are 
needed to quantify its effect to absorbed dose calculations using clinical data. 
 
Most of the quantification accuracy studies have been done using phantoms, which lacks 
the reality of clinical patient cases. However, Sanders et al. estimated urine activity 
concentration from SPECT/CT images and compared the results with urine samples 






SPECT/CT concentration estimates. These kind of measurements give realistic 
understanding of the quantification accuracy of SPECT/CT methods and would have 
improved this thesis also. 
 
The poor quantification accuracy of SPECT is mostly due to poor spatial and energy 
resolution of the gamma camera and this can be considered one of the limiting factors of 
SPECT image based quantification, and thus reliable dosimetry, especially for small 
organs or tumours. It should be noted that currently other clinically available imaging 
methods for therapeutic radiopharmaceuticals are not available, with the exception of 
PET for 90Y. 
 
Quantification accuracy is dependent on how imaging data is processed. As shown in 
Study I, compensation methods for confounding effects are important to improve 
quantification accuracy. However, iterative reconstruction is non-linear and has multiple 
parameters, which makes them more complex than analytical methods. Despite the 
complexity, iterative reconstruction algorithms are essential for quantitative SPECT 
imaging, because contrary to PET, SPECT attenuation correction has to be done during 
reconstruction and currently iterative methods are the only option for that. Due to 
complexity of iterative algorithms, the optimization of reconstruction parameters is 
laborious and an optimisation end point is hard to define. Simply put, reconstruction 
parameter optimisation is a trade-off between noise and quantification accuracy. In 
addition to parameters, variance in quantification is also dependent on the size of the 
source and the detected counts in raw projection data. For example, Cheng et al. optimised 
reconstruction parameters to improve DVH estimates using simulated data and they 
presented fifteen different iteration and filtering combinations for three studied organs 
(liver, kidney and renal cortices) at five different time points after injection [71].  
Reconstruction parameters (number of iterations and subsets) used in this thesis was a 
compromise between reconstruction time, quantification accuracy and image noise. 
Organ of interest, kidney, was also taken into consideration. Selection was based on 
multiple phantom measurements and thousands of image reconstructions carried out prior 
to this thesis (data not published). 
 
In addition to quantitative image reconstruction, image post-processing is also a major 
source of inaccuracy. Whether it is the determination of organ volume or activity in organ 
at different time points (TAC), defining the boundaries of region of interest produces 
substantial bias and variance to results. There are almost as many delineation methods as 
there are quantification or dosimetry studies. Mostly used methods are threshold or 
manual methods, although automatic segmentation methods have been utilised. Manual 
delineation is obviously very operator sensitive and prone to random errors. On the other 
hand, there is no correct threshold value for delineation, which is suitable for all SPECT 
data and source sizes, and thus the threshold method is also arbitrary. Despite several 
years of extensive research of the ideal delineation method for nuclear medicine images 
[72], the problem still remains unsolved. In this thesis, delineation was carried out 
manually along physical boundaries of the volume of interest with help from CT images 






manual delineation is usually relative easy to implement, though cumbersome in most 
cases. But in some cases where the region of interest is not visible in CT images, like 
tumours, manual delineation is impractical.  The delineation based on physical boundaries 
from CT image has its disadvantages, the delineation rule is explicit and it also gives the 
volume (mass), which is needed for absorbed dose calculation. 
 
Several studies have been carried out to solve the optimal number of SPECT acquisition 
time points for 177Lu-DOTATATE treatments [43, 73-75]. Three to four time points over 
a week are considered to be adequate to sample TAC of simple kinetics of 177Lu-
DOTATATE in kidneys. Dosimetry protocols with several imaging visits to the hospital 
are burdensome for patients and for the nuclear medicine imaging facility. In study III, 
the fast kidney dose (FKD) protocol with two acquisition time-points was found to be 
adequate for estimation of mean absorbed dose to kidneys and the FDK protocol was 
implemented in clinical practice in HUCH Comprehensive Cancer Center. However, the 
kinetics of radiopharmaceuticals are rarely as simply as earlier presented. For example, 
177Lu-DOTATATE has been shown to have stable uptake even up to 20 hours in tumours 
[64]. The aim of this thesis was to perform absorbed dose calculations in voxel-level. 
Clinical SPECT images are noisy due to low statistics in acquired projection data and 
inherent properties of iterative reconstruction algorithms. Because of that, a mixed and 
restricted voxel level TIAC calculation method was implemented. In comparison study 
IV, the implemented voxel level dose calculation method was found to be feasible for 
kidneys and estimated doses were comparable with OLINDA/EXM calculation based on 
whole kidney volume activities and kinetics. However, for other organs and tumours 
further studies are needed to verify the present TIAC calculation method. 
One part of this thesis was dedicated to absorbed dose calculations (study II). The study 
was designed to verify the fast sMC calculation method implemented in HIRD, and also 
to study photon cross-irradiation. Despite the relatively low abundance of photon emitted 
by 177Lu, it was found that photons from high uptake volumes can produce significant 
dose heterogeneity in tissues around the source volume or cross-irradiation dose from 
several sources can accumulate to a relative high sum. This result is important for voxel-
level dosimetry and examples of photon cross-irradiation was shown to be relevant in 
patients with low kidney uptake of 177Lu-DOTATATE or with high uptake tumour masses 
in nearby organs (Figures 5-11 and 5-12).  
There are other factors which also affect the dose calculation accuracy, but their effect 
can be considered to be minor compared to the factors reviewed above. Physical 
properties of radionuclide and decay data scheme have their uncertainties, but they are 
many folds smaller than other factors discussed earlier. Nevertheless, implementation of 








6.2 Future aspects 
 
Voxel-level dosimetry tools presented in this thesis can be implemented for other organs, 
radionuclides and imaging modalities than kidneys, 177Lu and SPECT. One very 
interesting future research topic is tumour dosimetry and dose response of 177Lu-
DOTATATE, which is scarcely studied [19]. Another obvious topic is the 
implementation of dosimetry methods presented in this thesis for 177Lu-PSMA 
treatments. 
 
Using state-of-the-art reconstruction methods, voxel based dose analysis methods like 
dose volume histogram analysis could help to gain more insight into dose response and 
help to predict treatment outcomes. With the help of dose heterogeneity information, 
sophisticated radiobiological models could be used, which are a normal convention in 
external radiation treatments. This could also help to predict possible normal tissue 
complication and tumour responses.  
 
In this thesis, all absorbed dose calculations were done after the patient received 
radionuclide therapy. Thus, dose calculations did not have a big predictive value, rather 
calculations were carried out for patient safety and legislation reasons and to follow up 
critical healthy tissue absorbed dose levels. In future, dosimetry needs also to be applied 
to predicted therapeutic response. DOTATATE can be radiolabelled with Gallium-68 
(68Ga) and then carry out the diagnostic imaging using PET. This gives possibilities to 
study radiopharmaceuticals kinetics before treatment and could help to choose patients 
who will benefit from the treatment. Due to the short half-life of 68Ga, predicting the 
kinetics of DOTATATE from PET imaging is challenging, but a physiologically based 
pharmacokinetic (PBPK) model has been proposed to tackle this problem [76].  
 
There are other dosimetry software packages available for radionuclide dosimetry (page 
10, Table 2-1). As quantitative SPECT imaging and image based dosimetry become more 
common, one big step for the whole nuclear medicine community is to harmonize 
dosimetry methods so that calculated absorbed dose is equal globally. Similar efforts have 
been carried out for harmonising the standardised uptake value [77], which is a semi-
quantitative measure used in diagnostic PET imaging. It would be important to carry out 









In this thesis, fundamental parts of radionuclide therapy dosimetry were studied and 
findings were used to develop voxel level dosimetry software for 177Lu-DOTATATE 
treatments. Software includes all the necessary steps from image reconstruction to 
absorbed dose calculations which streamlines daily practice. The voxel level dosimetry 
methodology was tested with phantoms and validated with patient data. The thesis 
reached its aims with the following main conclusions: 
 
I  An anthropomorphic phantom was used to show the importance of 
reconstruction compensation methods for 177Lu activity quantification. 
Combining attenuation, Monte-Carlo scatter and collimator-detector-
response compensation method dramatically improves quantification 
accuracy of small 177Lu sources. 
 
II For SPECT image based dosimetry with voxel size of 4 mm or higher, - 
radiation emitted by 177Lu can be considered to be locally absorbed. On the 
other hand, cross-irradiation from gamma radiation can accumulate to 
relatively high absorbed dose levels or produce notable dose heterogeneity. 
 
III Resident times of 177Lu-DOTATATE measured from kidney using small 
volume or whole kidney region of interests does not significantly differ. 
However, small volume method is operator dependent. In addition, a small 
volume placed on the most active volume produced higher absorbed doses 
than whole kidney method. This implies heterogeneous activity 
accumulation and absorbed dose to kidneys. 
 
IV Presented voxel level dosimetry software is feasible for kidney dosimetry 
of 177Lu-DOTATATE treated patients. Software includes also cross-
irradiation dose calculation from gamma emissions, which was shown to be 
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